Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (6503)	6/21/1998 10:05:00 AM
From: opalapril	Read Replies (2) \| Respond to of 17367

Thanks, Tharos, for the H-Q report from mid-1997. Odd that no one mentioned this before. It explains a lot. It also gives credence, I am afraid, to those who view the statistical P-2 efficacy results as too narrow and unimpressive for comfort. At bottom, this is the problem with rBPI. The molecule is "interesting", the theory is elegant, the compound is safe, but to date the results observed have been disappointingly modest -- even ambiguous. As for your follow-up post about the Oregon boy, I remember earlier versions of the same news item were careful to point out that he was not actually treated with Neuprex. BTW, the stat job at Xoma has been open for quite some time.